Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: ribosomal protein modulators - Eloxx Pharmaceuticals

Next Previous
Drug Profile

Research programme: ribosomal protein modulators - Eloxx Pharmaceuticals

Alternative Names: ERSG molecules - Eloxx Pharmaceuticals; Eukaryotic ribosomal selective glycosides - Eloxx Pharmaceuticals

Latest Information Update: 04 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Technion - Israel Institute of Technology
  • Developer Eloxx Pharmaceuticals
  • Class Eye disorder therapies; Glycosides; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Ribosomal protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cystic fibrosis
  • Discontinued Autosomal dominant polycystic kidney disease; Cystinuria; Eye disorders; Inborn genetic disorders; Lung disorders

Most Recent Events

  • 04 Aug 2023 Discontinued - Preclinical for Autosomal dominant polycystic kidney disease in Israel (unspecified route) (before August 2023) (Eloxx Pharmaceuticals Pipeline, August 2023)
  • 04 Aug 2023 Discontinued - Preclinical for Cystinuria in Israel (unspecified route) (before August 2023) (Eloxx Pharmaceuticals Pipeline, August 2023)
  • 04 Aug 2023 Discontinued - Preclinical for Eye disorders in Israel (Intravitreous) (before August 2023) (Eloxx Pharmaceuticals Pipeline, August 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top